Following the news that Pfizer/BioNTech will apply for authorisation of their Covid-19 vaccine Comirnaty for children ages 5–11 after showing positive initial data from a trial at a lower dose in this age group; Philipp Rosenbaum, Senior Healthcare Analyst at GlobalData, offers his view.   He said: “It will be a delicate measure to broadly […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!